how-to
How to Prepare a GRAS Notification: Step-by-Step
Table of Contents
- What the GRAS Notification Program Is and When to Use It
- FDA GRAS Notice Requirements Under 21 CFR Part 570 Subpart E
- Step-by-Step: How to Prepare a GRAS Notification
- Step 1: Define Substance Identity and Chemical Characterization
- Step 2: Document the Manufacturing Process and Specifications
- Step 3: Establish Intended Conditions of Use and Technical Effect
- Step 4: Build the Dietary Exposure Assessment
- Step 5: Assemble and Grade the Safety Evidence
- Step 6: Write the Safety Narrative and Secure Expert Consensus
- Step 7: Format and Submit
- Your GRAS Notification Checklist: Documents to Assemble Before Submission
- GRAS Notice Examples: What Strong and Weak Submissions Look Like
- The FDA GRAS Review Timeline and What Happens After You File
- Common Submission Errors and How to Fix Them Before Filing
- Conclusion
- Frequently Asked Questions
Last Updated: October 17, 2026
What the GRAS Notification Program Is and When to Use It
A GRAS notification is a voluntary submission to the FDA asking the agency to review your conclusion that a substance is Generally Recognized as Safe under the conditions you intend to use it. At Seven Hills Regulatory Services, we walk animal feed and pet food teams through this process regularly, and the learning curve is steeper than most founders expect. The Human Food GRAS program is notably different than the GRAS program for animal feed and pet food.
GRAS status rests on two pillars. The substance must be shown safe through scientific procedures, and that safety must be widely accepted by qualified experts. Both pillars need documented proof.
The FDA's GRAS notification program overview explains that the agency evaluates your basis and responds with a "no questions" letter when it agrees. That letter is not an approval. It is the agency saying it has no concerns about your safety conclusion.
GRAS Notice vs. Food Additive Petition: Choosing the Right Pathway
A food additive petition is mandatory premarket approval. A GRAS notice is a voluntary notification of a self-made safety determination. Choose GRAS when your ingredient has a documented safety basis and expert consensus behind it. Choose the petition route when the safety data is not public or the use is genuinely novel. The AFIC pathway is similar to the old AAFCO ingredient definition pathway.
FDA GRAS Notice Requirements Under 21 CFR Part 570 Subpart E
The FDA GRAS notice requirements under 21 CFR Part 570 Subpart E define exactly what your submission must contain. The eCFR text of 21 CFR Part 570 Subpart E is the controlling document, so read it before you draft anything.
Your notice must cover:
- Substance identity and chemical characterization
- Manufacturing process and ingredient specifications
- Intended conditions of use and technical effect
- Dietary exposure and estimated daily intake
- The safety narrative with supporting documentation
Skip a section and the FDA will likely respond that your basis is insufficient. That costs you a full review cycle.
Step-by-Step: How to Prepare a GRAS Notification
Preparing a GRAS notification follows a logical sequence, and the order matters because each section feeds the next. The workflow below turns the 21 CFR Part 570 Subpart E requirements into a sequenced dossier build.
Step 1: Define Substance Identity and Chemical Characterization
Start with substance identity. Name the substance, give its chemical formula or molecular description, and document its source, including whether it is isolated from a natural source, produced by fermentation, or synthesized.
A common mistake is describing identity in general terms. Regulators need specification limits with numbers and test methods, not adjectives. If your ingredient is a mixture or a fermentation product, characterize the components that drive the safety profile, not just the marketed name.
Step 2: Document the Manufacturing Process and Specifications
Describe the manufacturing process step by step, from raw materials through finished ingredient. Name the manufacturing controls that keep the process consistent, in-process limits, critical control points, and release testing.
The goal is to show that the substance you tested is the substance you will sell. If your safety studies used a pilot-scale material, explain how the commercial process compares and why the specifications cover any difference.
Step 3: Establish Intended Conditions of Use and Technical Effect
State your use level for each species and life stage, and explain the technical effect the ingredient provides, nutrient delivery, palatability, preservation, pellet binding, or another functional role. Intended use must match what your label will claim and what your exposure assessment will model. If you intend multiple uses, list each one with its own use level, because the exposure assessment has to combine them.
Step 4: Build the Dietary Exposure Assessment
The exposure assessment converts use levels and consumption data into an estimated daily intake for the relevant population groups. The mechanics are straightforward but easy to get wrong.
Document every input: the use level, the consumption value and its source, the population group, and the resulting estimated daily intake. If your estimated daily intake sits close to a no-observed-adverse-effect level, adjust the use level or add supporting studies before you file.
Step 5: Assemble and Grade the Safety Evidence
The safety section is not a literature dump. For each study you rely on, record the species, dose levels, duration, endpoints measured, and whether the study was conducted under accepted good laboratory practice or LGP-like conditions. Also diets and animal management should be reflective of US practices.
Schedule a Free 30-minute Consultation →
Where findings conflict, explain the weight you give each study and why. A weight-of-evidence summary that ranks studies by quality and relevance is far stronger than a stack of attachments.
Step 6: Write the Safety Narrative and Secure Expert Consensus
The safety narrative ties the identity, specifications, exposure assessment, and toxicology data into one argument that leads the reviewer from your substance to your conclusion. A GRAS Panel is not required. If using a panel, secure signed consensus statements from the qualified experts who have reviewed the full dossier, not just the GRAS summary. The experts' credentials and the basis for their conclusion should be documented.
Step 7: Format and Submit
Format the notice per FDA guidance for electronic submissions, flag confidential information for public-disclosure review, and confirm every required section is present before you file. A completeness check against the checklist in the next section catches most avoidable delays.
Your GRAS Notification Checklist: Documents to Assemble Before Submission
A GRAS notification checklist keeps your dossier complete. Assemble these before you draft the narrative:
- Substance identity statement with chemical characterization
- Manufacturing process description and manufacturing controls
- Ingredient specifications with test methods and specification limits
- Intended conditions of use by species and life stage
- Technical effect statement
- Dietary exposure assessment with consumption data and estimated daily intake
- Toxicology data and scientific literature review
- Weight of evidence summary
- Qualified experts' consensus statement (if using a GRAS Panel)
- Confidential information flagged for public disclosure review
- Electronic submission formatted per FDA guidance
GRAS Notice Examples: What Strong and Weak Submissions Look Like
Strong GRAS notice examples share one trait: every claim has a citation. A strong submission walks the reviewer from identity through exposure to safety without gaps. The safety narrative reads as one argument, not a pile of attachments.
Weak submissions look different. They cite studies without explaining relevance. They state a use level but never connect it to intake. They leave data gaps unaddressed and hope the reviewer misses them. Reviewers do not miss them.
The FDA GRAS Review Timeline and What Happens After You File
The FDA GRAS review timeline runs on the agency's own schedule. Filing starts a 30-day window for the FDA to screen your notice for completeness.
You can expect questions. The FDA may ask for clarification, additional data, or a revised exposure assessment. Answer promptly and completely.
After you receive a no questions letter, your work continues. Maintain your specifications, track real-world use, and keep your safety file current.
Common Submission Errors and How to Fix Them Before Filing
The most common submission errors are fixable before you file, and most of them trace back to a handful of root causes: incomplete characterization, unsupported uses, weak safety rationales, and avoidable disclosure problems.
Error | Why it happens | How to fix it before filing |
|---|---|---|
Vague identity | The team describes the ingredient by trade name instead of chemistry | Add chemical characterization, impurity limits, and test methods; confirm the tested material matches the commercial specification |
Unsupported use levels | Use levels are set by marketing rather than by exposure math | Recalculate estimated daily intake for every species and life stage; lower use levels or add studies if the margin is thin |
Exposure gaps | Consumption data are missing for a population group you name | Document a consumption value and source for every group; drop groups you cannot support |
Literature dumps | Studies are attached without explaining relevance | Grade each study for quality and relevance and explain how it supports the conclusion |
Weak safety rationale | The narrative lists data but does not argue from it | Rewrite as a weight-of-evidence argument that addresses conflicting findings and data gaps |
Missing expert consensus | Experts reviewed a summary, not the dossier | Secure signed statements from qualified experts who reviewed the full submission |
Confidentiality oversights | Proprietary details are left unmarked | Mark confidential information clearly and plan for public disclosure before filing |
A few of these deserve more than a line. On identity, the fix is not more prose, it is a specification table with assay range, impurity limits, and the analytical method for each parameter.
Conclusion
Preparing a GRAS notification is a documentation discipline, not a research sprint. Most delays trace back to gaps you can close before you file. If your team needs experienced eyes on the dossier, Seven Hills Regulatory Services brings animal scientists, toxicologists, and former FDA scientists to the review. We help you assemble the safety narrative, run the exposure assessment, and prepare for FDA questions. Schedule a free 30-minute consultation with Seven Hills Regulatory Services and file with confidence.
Frequently Asked Questions
How long does the FDA GRAS notification process take?
FDA aims to respond within ~200 days of filing, but the clock stops whenever the agency requests additional information, so real timelines often run longer. Your own preparation phase, from assembling substance identity data to finishing the safety narrative, typically takes several months before you even file. Building the dossier in parallel with toxicology and exposure work, rather than sequentially, is the biggest lever you control.
Can a GRAS notice cover an ingredient used in animal food?
Yes. The GRAS notification program accepts notices for substances used in animal food, including livestock feed and pet food, provided you establish safety for the target species and the intended conditions of use. Your dietary exposure assessment must use species-appropriate consumption data rather than human intake figures, and the safety narrative should address target animal safety as well as any residues relevant to human food derived from treated animals.
What is the difference between self-affirmed GRAS and an FDA GRAS notification?
Self-affirmed GRAS means your company, through qualified experts, concludes the substance is generally recognized as safe without filing with FDA. A GRAS notification is a voluntary submission asking FDA to review that conclusion and respond, ideally with a no-questions letter. Self-affirmation is faster and cheaper but carries no agency acknowledgment, which some buyers and retailers expect. A notification creates a public record and a written FDA response, which can shorten customer qualification cycles. Many firms self-affirm first and file a notification once the safety narrative is mature. The FDA is taking steps to eliminate the Self-GRAS option making Notifications mandatory.
What information must be included in an FDA GRAS notice?
Under 21 CFR Part 570 Subpart E, a notice must describe the substance's identity and chemical characterization, its manufacturing process and specification limits, the intended conditions of use and technical effect, and the basis for the GRAS conclusion. That basis includes a safety narrative, a dietary exposure assessment with estimated daily intake across population groups (if there is a HFS component), and supporting documentation such as toxicology data and the scientific literature you relied on.